The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML

Friederike Pastore; Philipp A. Greif; Stephanie Schneider; Bianka Ksienzyk; Gudrun Mellert; Evelyn Zellmeier; Jan Braess; Cristina M. Sauerland; Achim Heinecke; Utz Krug; Wolfgang E. Berdel; Thomas Buechner; Bernhard Woermann; Wolfgang Hiddemann; Karsten Spiekermann

doi:10.1371/journal.pone.0109759

Loading metrics

Open Access

Peer-reviewed

Research Article

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML

Friederike Pastore ,

* E-mail: Friederike.Pastore@med.uni-muenchen.de

Affiliations Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany, Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯
Philipp A. Greif,

Affiliations Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany, Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯
Stephanie Schneider,

Affiliation Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany
⨯
Bianka Ksienzyk,

Affiliation Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany
⨯
Gudrun Mellert,

Affiliation Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany
⨯
Evelyn Zellmeier,

Affiliation Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany
⨯
Jan Braess,

Affiliation Dept. of Oncology and Hematology, Krankenhaus Barmherzige Brüder, Regensburg, Germany
⨯
Cristina M. Sauerland,

Affiliation Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
⨯
Achim Heinecke,

Affiliation Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
⨯
Utz Krug,

Affiliation Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany
⨯
Wolfgang E. Berdel,

Affiliation Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany
⨯
Thomas Buechner,

Affiliation Dept. of Internal Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany
⨯
Bernhard Woermann,

Affiliation German Society of Hematology and Oncology, Berlin, Germany
⨯
Wolfgang Hiddemann,

Affiliations Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany, Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯
Karsten Spiekermann

Affiliations Laboratory for Leukemia Diagnostics, Dept. of Internal Medicine III, University Hospital Munich Großhadern, Ludwig-Maximilian-University (LMU), Munich, Germany, Clinical Cooperative Group Pathogenesis of Acute Myeloid Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany
⨯

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML

Friederike Pastore,
Philipp A. Greif,
Stephanie Schneider,
Bianka Ksienzyk,
Gudrun Mellert,
Evelyn Zellmeier,
Jan Braess,
Cristina M. Sauerland,
Achim Heinecke,
Utz Krug

Published: October 9, 2014
https://doi.org/10.1371/journal.pone.0109759

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Insertion mutation
Is the Subject Area "Insertion mutation" applicable to this article?

Thanks for your feedback.
Acute myeloid leukemia
Is the Subject Area "Acute myeloid leukemia" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Blood counts
Is the Subject Area "Blood counts" applicable to this article?

Thanks for your feedback.
Prognosis
Is the Subject Area "Prognosis" applicable to this article?

Thanks for your feedback.
Tyrosine
Is the Subject Area "Tyrosine" applicable to this article?

Thanks for your feedback.
Cytogenetics
Is the Subject Area "Cytogenetics" applicable to this article?

Thanks for your feedback.
Frameshift mutation
Is the Subject Area "Frameshift mutation" applicable to this article?

Thanks for your feedback.